logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
after Q4 2020
Caladrius Biosciences, Inc.
Final results from phase II clinical trial of CLBS12
Critical limb ischemia
after Q4 2020
Catalyst Pharmaceutical Partners Inc.
Top-line results from proof-of-concept phase III trial of Firdapse
Ambulatory patients with spinal muscular atrophy (SMA) type 3
after Q4 2020
Acceleron Pharma, Inc
Topline results from phase II study of Luspatercept (BEYOND)
Non-transfusion-dependent beta-thalassemia
after Q4 2020
ABIVAX SA
ABVX.PA
Top-line data from phase IIb clinical trial of ABX464 (ABX464-103)
Moderate to severe active ulcerative colitis
after Q4 2020
Mirum Pharmaceuticals Inc.
Top-line data readout phase III trial of Maralixibat(MARCH-PFIC)
Progressive Familial Intrahepatic Cholestasis in children
after Q4 2020
Alnylam Pharmaceuticals Inc.
Initial results from phase III study of Lumasiran (ILLUMINATE-C )
Advanced Primary Hyperoxaluria Type 1
after Q4 2020
ASLAN Pharmaceuticals
Interim readout from phase I multiple ascending dose study of ASLAN004
Moderate-severe atopic dermatitis
after Q4 2020
NextCure Inc
Initial data from the Phase 2 portion of phase I/II trial of NC31
Advanced or metastatic solid tumors
after Q4 2020
BiondVax Pharmaceuticals Ltd.
Results from phase 3 trial of M-001 vaccine
Influenza
after Q4 2020
Cabaletta Bio, Inc.
Acute safety data from first cohort of phase I trial of DSG3-CAART
Pemphigus Vulgaris
after Q4 2020
Prothena Corporation plc
Further update from Part 1 of phase II clinical study of Prasinezumab (PASADENA)
Early Parkinson's disease
after Q4 2020
ERYTECH Pharma S.A
Interim superiority analysis from Phase 3 clinical trial evaluating the efficacy and safety of eryaspase(TRYbeCA-1)
Advanced metastatic pancreatic cancer
2H 2020
ProQR Therapeutics
Updated data from phase Ib/II open-label extension study of Sepofarsen (INSIGHT)
Leber's congenital amaurosis 10
2H 2020
Gamida-Cell Ltd.
Additional data from phase I/II study of Omidubicel
severe aplastic anemia
2H 2020
MacroGenics Inc.
Data from final overall survival analysis of the SOPHIA study of Margetuximab
HER2-positive metastatic breast cancer
2H 2020
MacroGenics Inc.
Initial data from phase II/III study of Margetuximab plus and Retifanlimab (MAHOGANY)
As a front-line treatment for advanced gastric and gastroesophageal junction cancer
Jul 2020
Novavax Inc.
Preliminary immunogenicity and safety results from the phase I portion of the NVX-CoV2373 vaccine trial
Coronavirus vaccine
2H 2020
ADC Therapeutics
Interim safety and efficacy data from phase I part of phase Ib/II clinical trial of Loncastuximab tesirine in combination with ibrutinib
Relapsed or refractory DLBCL and mantle cell lymphoma
2H 2020
Vir Biotechnology
Data from first flu season of phase I/II clinical trial of VIR-2482
Influenza A
Q3 2020
Momenta Pharmaceuticals Inc
Additional data from Part B of phase I/II clinical trial of M254
Idiopathic thrombocytopenic purpura (ITP)
Q3 2020
RAPT Therapeutics, Inc.
Data from PoC study of RPT 193
Atopic dermatitis
2H 2020
Compugen Ltd
Initial data from phase I combination dose-escalation study evaluating COM701 with Opdivo
Advanced solid tumors
Q3 2020
Biohaven Pharmaceutical Holding Co Ltd.
Topline data from Phase 2/3 trial of Troriluzole adjunctive therapy
Obsessive Compulsive Disorder
2H 2020
TG Therapeutics Inc.
TGTX, TGTX.OB
Top-line data from phase III trial of Ublituximab monotherapy (ULTIMATE II)
Relapsing multiple sclerosis
2H 2020
TG Therapeutics Inc.
TGTX, TGTX.OB
Top-line data from phase III trial of Ublituximab monotherapy (ULTIMATE I)
Relapsing multiple sclerosis